# Aerium Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aerium-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.aeriumtx.com
- Latest round: Series A (Mar 22, 2022)
- Investors on record: 2

## About

Based in Massachusetts, US, and founded in 2021, Aerium Therapeutics, Inc., is a biopharmaceutical company involved in the discovery and development of antibodies and small-molecule antivirals against SARS-CoV-2 and other epidemic & pandemic threats. In March 2022, Aerium Therapeutics, Inc. raised Series A funding led by new investor Omega Funds, with participation from another new investor F-Prime Capital. As of March 2022, the company is being led by Rajeev Venkayya as its CEO. 

The company develops monoclonal antibodies against SARS-CoV-2 with potent neutralizing activity against Delta and Omicron variants. The company uses antibodies' high-resolution structural characterization to reveal non-overlapping epitopes and a synergistic mechanism of action and develops potential candidates for the treatment or prophylaxis of COVID-19 and variants emerging from SARS-CoV-2 strains.

The company intends to use the March 2022 funding to develop its two monoclonal antibodies for use in combination to prevent coronavirus infection and future pandemic threats.

## Funding rounds

- Series A, Mar 22, 2022 — F-Prime Capital, Omega Funds

## Investors

- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series A
- Omega Funds (https://capitalatlas.ai/funds/omega-funds) — Series A